Key facts
- Tr1x’s last known valuation is $135.0M (Jan 2023).
- It has raised $125.0M; the latest was Later Stage VC ($50.0M) in Oct 2025.
- Notable investors include Alexandria Venture Investments, California Institute for Regenerative Medicine, The Column Group.
- Status: Privately Held (backing).
- ·The complete investor list — 3 names
- ·Watchlist + deal alerts for Tr1x
- ·The full record, as it builds
Funding rounds
No funding rounds for Tr1x are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Tr1x
Developer of a regulatory T cell-based therapy platform designed to treat autoimmune and inflammatory diseases by restoring immune tolerance. The company offers genetically engineered, stable, inflammation-targeting Tr1-mimicking cells with localized cytokine release, enabling patients with immune-mediated conditions to benefit from durable and precise immune suppression without compromising protective responses.
- Sector
- Healthcare
- HQ
- San Diego, CA, United States
- Founded
- 2018
- Employees
- 41
- Website
- tr1x.bio/
- Ownership
- Privately Held (backing)
Tr1x doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Tr1x shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Tr1x in its N-PORT filings yet. We sweep new filings monthly.